Literature DB >> 32141819

Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome.

Eylem Karatay1, Özlem Gül Utku2.   

Abstract

BACKGROUND/AIMS: The objective of this study is to determine the role of circulating resolvin D1 (RvD1) in patients with constipation subtype of irritable bowel syndrome (IBS-C) and evaluate the relationship between abdominal pain severity and RvD1 levels.
MATERIALS AND METHODS: This research included 55 patients with IBS-C and 36 healthy controls. Controls were selected from patients who applied to our department with similar complaints as IBS but were not diagnosed with any type of pathology after further investigations. All participants underwent complete blood count, C-reactive protein (CRP), and RvD1 levels measurements. We also recorded abdominal pain severity and the number of bowel movements. Patients with IBS-C were compared with respect to the demographic features and laboratory measurements.
RESULTS: The median CRP concentration in patients with IBS-C was significantly higher than that of controls (p=0.003). However, the median RvD1 concentration was significantly lower in the IBS group than that of the control group (p<0.001). The receiver operating characteristic curve analyses revealed that RvD1 concentration lower than 0.47 ng/mL and CRP concentration higher than 3.40 mg/L may identify patients with IBS-C with a high specificity. In the IBS group, there was a strong negative correlation between abdominal pain severity and RvD1 concentration (r=-0.766, p=0.001).
CONCLUSION: This research demonstrates that patients with IBS-C have higher CRP and lower RvD1 concentrations than healthy controls. Both RvD1 and CRP concentrations predict the presence of IBS-C. Additionally, RvD1 concentrations decreased with the increase in abdominal pain severity. Further research works are needed for investigating the role of the RvD1 analogs in the treatment of IBS.

Entities:  

Year:  2020        PMID: 32141819      PMCID: PMC7062141          DOI: 10.5152/tjg.2020.19751

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  30 in total

1.  Mediators and receptors in the resolution of inflammation: drug targeting opportunities.

Authors:  A G Stewart
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

Review 2.  Roles of resolvins in the resolution of acute inflammation.

Authors:  Qing Qu; Wenjuan Xuan; Guo-Huang Fan
Journal:  Cell Biol Int       Date:  2014-09-17       Impact factor: 3.612

Review 3.  Irritable bowel syndrome: a clinical review.

Authors:  William D Chey; Jacob Kurlander; Shanti Eswaran
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

Review 4.  Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review.

Authors:  Alexander C Ford; Nicholas J Talley
Journal:  J Gastroenterol       Date:  2011-02-18       Impact factor: 7.527

5.  Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.

Authors:  Pierre Paré; James Gray; Sy Lam; Robert Balshaw; Shideh Khorasheh; Martin Barbeau; Suzanne Kelly; Christopher R McBurney
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

6.  A pilot study of colonic B cell pattern in irritable bowel syndrome.

Authors:  Johan Forshammar; Stefan Isaksson; Hans Strid; Per-Ove Stotzer; Henrik Sjövall; Magnus Simrén; Lena Ohman
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

Review 7.  A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution.

Authors:  Charles N Serhan
Journal:  Histochem Cell Biol       Date:  2004-08-21       Impact factor: 4.304

8.  Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors.

Authors:  Timothy G Dinan; Gerard Clarke; Eamonn M M Quigley; Lucinda V Scott; Fergus Shanahan; John Cryan; John Cooney; P W N Keeling
Journal:  Am J Gastroenterol       Date:  2008-09-10       Impact factor: 10.864

9.  Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.

Authors:  Charles N Serhan; Song Hong; Karsten Gronert; Sean P Colgan; Pallavi R Devchand; Gudrun Mirick; Rose-Laure Moussignac
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

Review 10.  The role of inflammation in irritable bowel syndrome (IBS).

Authors:  Qin Xiang Ng; Alex Yu Sen Soh; Wayren Loke; Donovan Yutong Lim; Wee-Song Yeo
Journal:  J Inflamm Res       Date:  2018-09-21
View more
  2 in total

1.  Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro.

Authors:  Aimeé Salas-Hernández; Claudio Espinoza-Pérez; Raúl Vivar; Jenaro Espitia-Corredor; José Lillo; Pablo Parra-Flores; Carlos F Sánchez-Ferrer; Concepción Peiró; Guillermo Díaz-Araya
Journal:  Mol Biol Rep       Date:  2021-01-18       Impact factor: 2.316

2.  Inflammation in Irritable Bowel Syndrome (IBS): Role of Psyllium Fiber Supplementation in Decreasing Inflammation and Physiological Management of IBS.

Authors:  Pankaj Garg
Journal:  Turk J Gastroenterol       Date:  2021-01       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.